Skip to main content
S&P 5007,725.14+0.08%DOW52,118.94+0.96%NASDAQ26,598.26-0.35%BTC$82,194.00+0.76%ETH$2,442.75+0.77%GOLD$4,178.40+1.72%OIL$96.45+2.72%
Smart Investors Daily
SID Premium
PE

NYSE · PEN

Penumbra, Inc.

Healthcare · Medical - Devices

$320.12

Up+$0.86 (+0.27%)

Updated Oct 15, 2026, 6:39 PM

SID Score

5.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
12.2B
P/E ratio
74.22
Dividend yield
0.00%
52-week range
$221.26 – $362.41
Volume
272.34K
Avg. volume
443.1K

Price performance · PEN

PEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 14, 2026

PEN closed at $320.12 after 21 trading sessions, up 0.54% for the selected period.

Last close
$320.12
Period change
+0.54%
Period low
$316.35
Period high
$320.96
Daily close
View OHLC price history
PEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 14, 2026$320.41$320.42$319.25$320.12272.34K
Oct 13, 2026$320.93$320.99$318.26$320.01216.89K
Oct 12, 2026$319.91$320.97$318.97$320.96277.22K
Oct 9, 2026$317.06$319.53$317.06$319.40555.3K
Oct 8, 2026$316.61$317.52$316.53$317.52379.36K
Oct 7, 2026$316.62$317.74$316.32$316.35366.19K
Oct 6, 2026$317.10$318.005$316.87$317.05308.41K
Oct 5, 2026$318.23$318.4699$317.10$317.11368.27K
Oct 2, 2026$318.37$318.37$316.78$317.55239.68K
Oct 1, 2026$318.38$318.925$317.92$318.00350.52K
Sep 30, 2026$318.51$319.19$318.24$318.34378.22K
Sep 29, 2026$318.73$318.98$318.1401$318.86189.85K
Sep 28, 2026$318.91$319.33$318.11$319.18189.48K
Sep 25, 2026$319.28$319.61$318.17$318.89228.15K
Sep 24, 2026$318.98$320.27$318.33$319.72482.95K
Sep 23, 2026$319.46$320.26$318.40$319.44410.63K
Sep 22, 2026$319.80$319.80$318.49$319.39797.92K
Sep 21, 2026$317.38$318.78$316.7743$318.78293.93K
Sep 18, 2026$319.19$319.19$317.50$317.60994.5K
Sep 17, 2026$319.20$319.20$317.95$318.87416.08K
Sep 16, 2026$317.30$319.33$317.30$318.40816.98K

Latest PEN news

The latest Smart Investors Daily articles mentioning PEN.

Stock researchCompany · Overview

PEN research

Overview

Company profile and research snapshot.

Company profile

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$311.00
Implied upside
—
Analysts
—
PEN recent ratings
DateFirmRatingTarget
Jul 6, 2026Evercore ISI GroupOutperform—
Jun 11, 2026RBC CapitalSector Perform—
May 7, 2026CitigroupNeutral—
May 7, 2026Evercore ISI GroupOutperform—
Feb 26, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus

Penumbra (PEN) is back in focus after new clinical data from its STORM-PE and STRIKE-PE studies linked real-world wearable activity to recovery outcomes in pulmonary embolism patients treated with its CAVT technology. Recent clinical headlines have landed against a relatively quiet tape for Penumbra, with the share price easing 1.8% over the past month and 0.6% over the past week, even as the year-to-date share price return is positive and the 1-year total shareholder return of 22.2% points...

Yahoo · Oct 6, 2026

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Penumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test. The findings were presented at this week's Vascular InterVentional Advances (VIVA) meeting.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By